Publisher: Medip Academy   (Total: 12 journals)   [Sort by number of followers]

Showing 1 - 12 of 12 Journals sorted alphabetically
Intl. J. of Advances in Medicine     Open Access   (Followers: 2)
Intl. J. of Basic & Clinical Pharmacology     Open Access   (Followers: 2)
Intl. J. of Clinical Trials     Open Access   (Followers: 3)
Intl. J. of Community Medicine and Public Health     Open Access   (Followers: 7)
Intl. J. of Contemporary Pediatrics     Open Access   (Followers: 6)
Intl. J. of Otorhinolaryngology and Head and Neck Surgery     Open Access  
Intl. J. of Reproduction, Contraception, Obstetrics and Gynecology     Open Access   (Followers: 14)
Intl. J. of Research in Dermatology     Open Access   (Followers: 1)
Intl. J. of Research in Medical Sciences     Open Access   (Followers: 5)
Intl. J. of Research in Orthopaedics     Open Access  
Intl. J. of Scientific Reports     Open Access   (Followers: 4)
Intl. Surgery J.     Open Access   (Followers: 3)
Similar Journals
Journal Cover
International Journal of Clinical Trials
Number of Followers: 3  

  This is an Open Access Journal Open Access journal
ISSN (Print) 2349-3240 - ISSN (Online) 2349-3259
Published by Medip Academy Homepage  [12 journals]
  • Dihydroartemisinin-piperaquine for the routine treatment of uncomplicated
           malaria in Northern Ghana

    • Authors: Abraham R. Oduro, Samuel Chatio, Emmanuel Ayamba, Thomas Anyorigiya, Fred Binka, Lucas Amenga-Etego
      Pages: 1 - 10
      Abstract: Background: Dihydroartemisinin-piperaquine is a first line treatment for uncomplicated malaria in Ghana. A facility-based study was undertaken to examine the effectiveness of the treatment in the routine health care system.Methods: The study was undertaken at the Navrongo demographic surveillance area. Patients presenting with acute febrile illness were enrolled after informed consented and confirmation by microscopy. Patients were randomized into supervised group who received treatment under direct observation and unsupervised group which had only the first treatment given under supervision. Treatment was according to bodyweight and 42 days follow-up was undertaken.Results: A total of 194 patients were enrolled; 54.1% were females and 51% had supervised treatment. The median age and weight were 6.7 years and 20.0 kg respectively. Mean baseline temperature, haemoglobin concentration and parasite density were, 37.6 oC, 11.1 g/dl and 11,098 parasites per microliter of blood respectively. Study completion rate was 93.3%, day 42 polymerase chain reaction-unadjusted adequate clinical and parasitological responses rate (ACPR) was 93.4% by evaluable and 87.1 % by intention-to-treat (ITT). The day 42 ACPR by evaluable was 92.3% in the supervised arm compared to 94.4% in the unsupervised arm. The day 42 ACPR by ITT was 85.7% in the supervised and 88.5% in the unsupervised arms. The fever resolution and haemoglobin concentration changes for the two arms were similar.Conclusions: The results show that dihydroartemisinin-piperaquine is effective and good first-line antimalarial in the routine health delivery system.
      PubDate: 2020-01-24
      DOI: 10.18203/2349-3259.ijct20200200
      Issue No: Vol. 7, No. 1 (2020)
       
  • Oncology patient preferences in reporting on symptoms

    • Authors: Alyssa L. Peechatka, Millie Gerzon, Jenny J. Ly, Susan M. Dallabrida
      Pages: 11 - 17
      Abstract: Background: Collecting patient reported outcomes (PROs) in oncology clinical trials is becoming increasingly important. However, there is limited consensus on the most appropriate frequency of PRO administration in oncology trials.  The aim of this preliminary study is to examine the perspective of participants with a cancer diagnosis on the importance of completing PROs and to identify at what frequency participants prefer to report on their cancer-related symptoms.Methods: 166 participants with a self-reported cancer diagnosis completed a multiple-choice online survey regarding perceptions of symptom importance and reporting preferences.Results: When asked about the benefit of reporting oncology-related symptoms daily, 44% of participants indicated there would be “very much” a benefit, 29% indicated there would be “quite a bit” of benefit, and 17% indicated there would be “somewhat” of a benefit. When asked about how frequently they would prefer to report symptoms, 41% of participants preferred “as they occur,” 36% preferred “once a day,” 18% preferred “once a week,” 4% preferred “twice a day,” and 1% preferred “every 4 hours”.Conclusions: PROs in oncology clinical research are most often collected at weekly, monthly, or longer intervals; however, meaningful fluctuations in cancer-related symptoms can occur more frequently. While concerns regarding patient burden are often raised to support infrequent reporting, these data suggest that participants would like to report symptoms with greater frequency, as episodic and daily reporting options were most popular. Based on these data, more frequent PRO data capture is not only feasible but perceived as important by individuals with cancer.
      PubDate: 2020-01-24
      DOI: 10.18203/2349-3259.ijct20200201
      Issue No: Vol. 7, No. 1 (2020)
       
  • Randomized response surface pathway design with skewed starting point and
           stochastic dose window

    • Authors: Trond Holand, Øystein Evensen, Sagita Dewi, Stig Larsen
      Pages: 18 - 27
      Abstract: Background: The aim was to introduce response surface pathway (RSP)-design with skewed starting value and stochastic dose-window to estimate optimal efficacy dose (OED) of BP-C2 after IL-1β stimulation in Atlantic salmon.Methods: 54 healthy smolt of Atlantic salmon between 50 and 100 g before habituated to salt water were included. The study was conducted as a one-dimensional, randomized between-patient three-level RSP designed trial with one interventional- and one response variable and odd outcomes. The interventional variable was intraperitoneal injected BPC2 with skewed starting dose of 0.10 mg/100 g related to the initial dose-window <0.02-0.5 mg/100 g. The response variable was the Ct-value of mRNA IL-1β expression 24 hours after injection.Results: Skewed starting value of 0.10 mg/100 g was chosen in the first design-level with a dose-window of <0.0-0.20]. The three smolt obtained a reduction in Ct-value above 15%, and the dose-window adjusted with the lower boundary equals the previous dose. The five smolt at second design-level received 0.16 mg/100g with a dose-window [0.10-0.22]. Four smolt obtained above 15% and one of 0.5% reduction in cycle threshold (Ct)-value. Six smolt in the third design-level received 0.21 mg/100 g and one 0.16 mg/100 g. The mean Ct-value was reduced from 30.0 in the unstimulated situation to 25.0, 24.8 and 26.4 after BP-C2 stimulation of 0.10, 0.16 and 0.21 mg/100 g, respectively. The OED of BP-C2 related to IL-1β was estimated to 0.14 mg/100 g.Conclusions: Skewed starting value in the initial dose-window made the K-adjustment factor and dose-window stochastic. The RSP-procedure works in accordance to the expectation and estimated OED of BP-C2 sufficiently.
      PubDate: 2020-01-24
      DOI: 10.18203/2349-3259.ijct20200202
      Issue No: Vol. 7, No. 1 (2020)
       
  • Comparative evaluation of post-operative analgesic effects of
           intraperitoneal levobupivacaine plus fentanyl and levobupivacaine plus
           tramadol in patients undergoing laparoscopic cholecystectomy

    • Authors: Madan lal Katoch, Loveleen Kour
      Pages: 28 - 31
      Abstract: Background: Laparoscopic cholecystectomy is commonly performed as a day care procedure for treating symptomatic gallstones. Suitability of patient discharge from the inpatient facility depends upon adequacy of postoperative pain control. Among the various modalities for pain relief, intraperitoneal local anaesthetic has become an important approach. In this study we aimed at comparing the post-operative analgesic effects of intraperitoneal levobupivacaine plus fentanyl and levobupivacaine plus tramadol in patients after laparoscopic cholecystectomy. The objective of this study was to determine which adjuvant drug was superior to the other in terms of prolonging the analgesic effects of levobupivacaine in post-operative period of laparoscopic cholecystectomy.Methods: A total of 90 patients undergoing laparoscopic cholecystectomy were selected. They were divided into three groups: Group L- received 50 ml of 0.25% levobupivacaine; Group LT- received 0.25% of levobupivacaine and tramadol 2 ml (50 ml total); group LF- received 0.25% levobupivacaine plus fentanyl 2 ml (50 ml total). Postoperative pain was assessed using visual analogue scale.Results: The combination of levobupivacaine fentanyl and levobupivacaine tramadol was superior to plain levobupivacaine for reducing postoperative pain. No significant difference was found between Group LT and LF with respect to first analgesic and total analgesic requirement. However significant difference was found between LF and L; and between LT and L.Conclusions: Levobupivacaine should be used along with adjuncts either tramadol or fentanyl. 
      PubDate: 2020-01-24
      DOI: 10.18203/2349-3259.ijct20200203
      Issue No: Vol. 7, No. 1 (2020)
       
  • Evaluation of neo adjuvant chemotherapy response in patients with locally
           advanced breast cancer

    • Authors: Nallamothu Murali Krishna, C. Mandava Radha Mani, Veera Abhinav C., T. Jaya Chandra
      Pages: 32 - 34
      Abstract: Background: Carcinoma of the breast from the very beginning has been a feared disease. Advanced disease is treated by neoadjuvant chemotherapy (NACT). With this, a study was conducted to evaluate the pathologic response to NACT in locally advanced breast cancer.Methods: Study was conducted in GSL Medical College, approved by institutional ethics committee, females aged >18 years with locally advanced breast cancer were included in the study. Female <18 years and breast cancer male were not considered. The dimensions are marked and size of the lump compared before and after NACT. Chi-square test was used to find out the significance of study parameters; p<0.05 was considered statistically significant.Results: Total 110 patients were included in the study, mean age was 50.63±10.76 years and 53% were in pre menopausal women. When pathological response was considered, 12.7% had complete response, 66.4% had partial response and 20.9% had no response to NACT; statistically there was significant difference between pre and post treatment tumor sizes (p<0.05).Conclusions: Most of the individuals belonged to premenopausal group. Tumour size showed significant decrease after NACT. The overall response rate (complete and partial) after NACT was significant in our study group.
      PubDate: 2020-01-24
      DOI: 10.18203/2349-3259.ijct20200204
      Issue No: Vol. 7, No. 1 (2020)
       
  • Response of osteoarthritis biomarkers after a rehabilitation program:
           study protocol

    • Authors: Eliane Antonioli, Felipe B. D. Oliveira, Rosana R. Campedelli, Alessandro R. Zorzi, Danielli Specialli, Sudha Agarwal, Mario Ferretti
      Pages: 35 - 42
      Abstract: Background: Knee osteoarthritis is a progressive degenerative joint disease and remains a leading cause of pain, physical impairment and decline in health-related quality of life in adults.   Despite its incidence being amongst the highest in chronic diseases, effective biomarkers are not available to assist in its management. The main goal of this study is to identify mediators that serve as biomarkers and investigate if the levels of these biomarkers will be correlated to the efficacy of a rehabilitation program.Methods: This is a prospective cohort study with 65 participants. Patients with mild-to-moderate symptomatic knee osteoarthritis will be recruited. The Rehabilitation Program will consist of three session/week during eight weeks. Assessment about functional evaluation will be performed before and after treatment, using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and EuroQOL-5D (Euro quality of life - five dimension) scales, Visual Analog Scale (VAS), and physical function tests (time up and go, isometric strength testing and kinematic gait analysis). Serum levels of classical pro-inflammatory cytokines, hyaluronan and high mobility group box 1 protein (HMGB-1) will be evaluated. The primary outcome is the change in WOMAC scale from baseline to end. Statistical analyses will be used to determine correlation of physical improvement and serum biomarkers. Adverse events will be monitored throughout the study.Conclusions: This trial expect to study the correlation between the anti-inflammatory effects of rehabilitation program derived factors that may be involved in suppressing cytokine induction via suppressing HMGB-1.Trial registration: Clinicaltrials.gov - NCT02964624.
      PubDate: 2020-01-24
      DOI: 10.18203/2349-3259.ijct20200205
      Issue No: Vol. 7, No. 1 (2020)
       
  • A quasi-experimental study on exploring the use of mobile phone technology
           for optimizing, tracking and responding to children's developmental
           progress in Korogocho, Nairobi, Kenya: study protocol

    • Authors: Patricia Kitsao Wekulo, Margaret Nampijja, Domnick O. Okullo, Kenneth O. Okelo, Milka Njeri, Silas Onyango, Elizabeth Kimani Murage
      Pages: 43 - 49
      Abstract: Background: The massive use of technology can be leveraged to facilitate access to growth and development programs for children. Existing programs supporting such initiatives for children younger than three years are inadequate and not accessible to most families. In most cases, primary caregivers are unable to identify delayed milestones in their children’s growth and development due to inadequate information. They therefore often report the cases when they have become very severe and difficult to reverse. In order to promote early identification of possible developmental delays, African Population and Health Research Center together with Val Partners will develop, implement and evaluate the use of mobile phone technology to help caregivers track their children's developmental outcomes.Methods: The study will employ a quasi-experimental design and will use a mixed-methods approach combining quantitative and qualitative methodologies. In one arm, 110 caregivers will be trained on the use of a mobile phone application to assess child growth and development. The other arm, with 110 caregivers, will receive standard care provided by community health volunteers. Child developmental outcomes will be assessed in both arms. Feasibility of the intervention will be assessed qualitatively. Performance data will be compared across the two arms using mixed linear models to assess the effect of the intervention on child development.Conclusions: The findings are expected to provide evidence on whether the intervention is feasible and has an effect on child developmental outcomes. The results will inform the scalability and sustainability of the project.Trial Registration: The trial has been registered with the Pan African Clinical Trial Registry (www.pactr.org) database (ID number: PACTR201905787868050).
      PubDate: 2020-01-24
      DOI: 10.18203/2349-3259.ijct20200206
      Issue No: Vol. 7, No. 1 (2020)
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 34.204.171.214
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-